Kanvas Biosciences Raises $12.5M in Funding to Advance Microbiome Therapeutics

Kanvas Biosciences raises additional funding

Kanvas Biosciences (Linkedin), a spatial biology company specializing in live biotherapeutics for microbiome-associated diseases, recently secured an additional $12.5M in funding. With a total funding of $29.5M, Kanvas Biosciences aims to improve cancer treatment outcomes and target patients resistant to immune checkpoint inhibitors.

Funding Amount: $12.5 million (Total: $29.5 million)

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Matthew Cheng (CEO Linkedin)

What Kanvas Biosciences needs to buy: Companies specializing in microbiome research, drug development, manufacturing and production solutions, and clinical trial support are ideal partners for Kanvas Biosciences. Collaborations in these areas will help advance their live biotherapeutics, conduct clinical trials, and bring innovative treatments to patients with microbiome-associated diseases.